Trials / Terminated
TerminatedNCT00500500
Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease
Effect of EGb 761® on the Ratio of the Isoforms of the Protein Precursor of Beta Amyloid Platelets on Patients With Mild to Moderate Alzheimer's Disease. A Phase II, Randomised, Double-blind Trial, on Parallel Groups Versus Placebo.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to measure the effect of EGb 761® versus placebo on the ratio of the isoform of the protein precursor of beta amyloid platelets, in patients with mild to moderate Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EGb 761® (Tanakan®) |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2007-07-12
- Last updated
- 2023-06-26
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00500500. Inclusion in this directory is not an endorsement.